Shehab N, Lovegrove M C, Geller A I,et al. US emergency department visits for outpatient adverse drug events, 2013-2014 [J]. JAMA, 2016, 316(20): 2115-2125.
Zheng Y Y,Wu T T, Yang Y,et al. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial [J]. Eur Heart J Cardiovasc Pharmacother, 2020, 6(4): 211-221.
[6]
Sibbing D, Aradi D, Alexopoulos D,et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention [J]. JACC Cardiovasc Interv, 2019, 12(16): 1521-1537.
Jiang H,Wang H, Liang B,et al. Prognostic implication of systemic inflammatory state on antiplatelet effect in patients after percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective cohort study [J]. Medicine (Baltimore), 2021, 100(37): e27214.
[9]
Page M J, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection [J]. Semin Thromb Hemost, 2020, 46(3): 302-319.
[10]
Houck K L, Yuan H, Tian Y,et al. Physical proximity and functional cooperation of glycoprotein 130 and glycoprotein VI in platelet membrane lipid rafts [J]. J Thromb Haemost, 2019, 17(9): 1500-1510.
[11]
Cavallari L H. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention [J]. Expert Rev Cardiovasc Ther, 2017, 15(8): 581-589.
[12]
Neumann F J, Sousa-Uva M, Ahlsson A,et al. 2018 ESC/EACTS guidelines on myocardial revascularization [J]. Eur Heart J, 2019, 40(2): 87-165.
[13]
Tang Y D, Wang W, Yang M,et al. Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the creative trial [J]. Circulation, 2018, 137(21): 2231-2245.
Byrne R A, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The andreas grüntzig lecture ESC 2014 [J]. Eur Heart J, 2015, 36(47): 3320-3331.
[16]
Collet J P, Thiele H, Barbato E,et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation [J]. Eur Heart J, 2021, 42(14): 1289-1367.
[17]
Sibbing D, Aradi D, Jacobshagen C,et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (Tropical-ACS): a randomised, open-label, multicentre trial [J]. Lancet, 2017, 390(14): 1747-1757.
[18]
Cuisset T, Deharo P, Quilici J,et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the topic (timing of platelet inhibition after acute coronary syndrome) randomized study [J]. Eur Heart J, 2017, 38(41): 3070-3078.
[19]
Park M W, Kim C J, Kim M C,et al. A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the talos-ami trial [J]. Eur Intervent, 2021, 16(14): 1170-1176.
[20]
Hassan S S, Stankowski T, Marczak J,et al. Timing strategy of preoperative aspirin and its impact on early outcomes in patients undergoing coronary artery bypass grafting: a propensity score matching analysis [J]. J Surg Res, 2020, 246: 251-259.
[21]
Vuilliomenet T, Gebhard C, Bizzozero C,et al. Discontinuation of dual antiplatelet therapy and bleeding in intensive care in patients undergoing urgent coronary artery bypass grafting: a retrospective analysis [J]. Interact Cardiovasc Thorac Surg, 2019, 28(5): 665-673.
[22]
Mahla E, Suarez T A, Bliden K P,et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (Target-CABG) study [J]. Circ Cardiovasc Interv, 2012, 5(2): 261-269.
[23]
Mannacio V, Meier P, Antignano A,et al. Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute coronary syndrome: a case-control study [J]. J Thorac Cardiovasc Surg, 2014, 148(4): 1299-1306.
[24]
Boer C, Meesters M I, Milojevic M,et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery [J]. J Cardiothorac Vasc Anesth, 2018, 32(1): 88-120.
2022, Vol. 33 
